Searchable abstracts of presentations at key conferences in endocrinology

ea0034p42 | Clinical biochemistry | SFEBES2014

Urinary 3-methoxytyramine as a biomarker of phaeochromocytoma and paraganglioma tumours

Neophytou Christina , Darch Sarah , Gill Jasdeep Singh , Hancock Maggie , Meeran Karim , Palazzo Fausto , Tan Tricia

Phaeochromocytomas (PCC) and paragangliomas (PGL) are rare tumours derived from the sympathetic or parasympathetic paraganglia. They characteristically secrete catecholamines (noradrenaline/adrenaline/dopamine), which are metabolised to the metanephrines (normetadrenaline/metadrenaline/3-MT respectively). These tumour markers can be detected in acidified 24-h urine collections as first-line investigative tests. Plasma 3-MT has been characterised as a biomarker of metastatic PG...

ea0031p159 | Neoplasia, cancer and late effects | SFEBES2013

The relationship between anatomical location of phaeochromocytoma and paraganglioma and their secretory properties

Lim Chung Thong , Gill Jasdeep , Ramachandran Radha , Brook Susan E , Martin Niamh M , Dhillo Waljit , Todd Jeannie , Palazzo Fausto , Caplin Martyn , Bouloux Pierre , Meeran Karim , Tan Tricia , Khoo Bernard

Background: Phaeochromocytomas (PCC) and paragangliomas (PGL) are neuroendocrine tumours that can secrete catecholamines. PCC are found in the adrenals, whereas PGL are found at any level between the skull base to the pelvis. More than 25% of cases are associated with mutations in susceptibility genes such as the SDH subunits. Screening for PCC/PGL crucially depends on detection of biochemical markers such as catecholamines and metanephrines (catecholamine metabolites).<p ...